These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21683249)

  • 1. Serpins and the complement system.
    Beinrohr L; Murray-Rust TA; Dyksterhuis L; Závodszky P; Gál P; Pike RN; Wijeyewickrema LC
    Methods Enzymol; 2011; 499():55-75. PubMed ID: 21683249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding.
    Rossi V; Bally I; Ancelet S; Xu Y; Frémeaux-Bacchi V; Vivès RR; Sadir R; Thielens N; Arlaud GJ
    J Immunol; 2010 May; 184(9):4982-9. PubMed ID: 20351192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
    Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
    Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of C1-inhibitor function by binding to type IV collagen and heparin.
    Patston PA; Schapira M
    Biochem Biophys Res Commun; 1997 Jan; 230(3):597-601. PubMed ID: 9015369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.
    Wijeyewickrema LC; Lameignere E; Hor L; Duncan RC; Shiba T; Travers RJ; Kapopara PR; Lei V; Smith SA; Kim H; Morrissey JH; Pike RN; Conway EM
    Blood; 2016 Sep; 128(13):1766-76. PubMed ID: 27338096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.
    Weiss V; Engel J
    Hoppe Seylers Z Physiol Chem; 1983 Mar; 364(3):295-301. PubMed ID: 6602754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
    Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
    J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of C1 inhibitor.
    Davis AE
    Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.
    Bos IG; Lubbers YT; Roem D; Abrahams JP; Hack CE; Eldering E
    J Biol Chem; 2003 Aug; 278(32):29463-70. PubMed ID: 12773530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor.
    Bos IG; de Bruin EC; Karuntu YA; Modderman PW; Eldering E; Hack CE
    Biochim Biophys Acta; 2003 May; 1648(1-2):75-83. PubMed ID: 12758149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
    Zahedi R; Wisnieski J; Davis AE
    J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HIV-1 protease cleavage site in human C1-inhibitor.
    Gerencer M; Burek V
    Virus Res; 2004 Sep; 105(1):97-100. PubMed ID: 15325085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
    Harpel PC; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):593-604. PubMed ID: 123251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional aspects of C1-inhibitor.
    Bos IG; Hack CE; Abrahams JP
    Immunobiology; 2002 Sep; 205(4-5):518-33. PubMed ID: 12396012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis of the serpin domain of C1 inhibitor.
    Coutinho M; Aulak KS; Davis AE
    J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants.
    Eldering E; Huijbregts CC; Nuijens JH; Hack CE
    Behring Inst Mitt; 1993 Dec; (93):125-30. PubMed ID: 8172559
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of recombinant C1 inhibitor P1 variants.
    Eldering E; Huijbregts CC; Lubbers YT; Longstaff C; Hack CE
    J Biol Chem; 1992 Apr; 267(10):7013-20. PubMed ID: 1551909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms.
    Davis AE; Aulak K; Parad RB; Stecklein HP; Eldering E; Hack CE; Kramer J; Strunk RC; Bissler J; Rosen FS
    Nat Genet; 1992 Aug; 1(5):354-8. PubMed ID: 1363816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.
    Cai S; Davis AE
    J Immunol; 2003 Nov; 171(9):4786-91. PubMed ID: 14568956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1.
    Murray-Rust TA; Kerr FK; Thomas AR; Wu T; Yongqing T; Ong PC; Quinsey NS; Whisstock JC; Wagenaar-Bos IC; Freeman C; Pike RN
    Biochem J; 2009 Aug; 422(2):295-303. PubMed ID: 19522701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.